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INTRODUCTION
Growth hormone (GH) has direct and indirect actions through which it stimulates growth of skeletal and other tissues, and influences the availability of metabolic fuels (Davidson, 1987; Isaksson et al. 1987) . The growth promoting actions of G H are 'indirect' and are largely mediated through generation of the insulin-like growth factor, IGF-I , which may act both as an endocrine and paracrine hormone (Isaksson et al. 1987) . The 'direct' actions of G H are predominantly antagonistic to insulin, although there are acute insulin-like effects of uncertain physiological significance (Fig. I) . Thus, there is an important interrelationship between the actions of GH, nutrition and growth.
G H is released from the human pituitary in a pulsatile manner. The pituitary has a unique anatomical relationship with the hypothalamus, such that the only blood supply to The growth-promoting effects are mediated predominantly through local tissue generation of insulin-like growth factor (IGF-1). Acute insulin-like effects have been demonstrated within 2 h of GH administration, before tissues become refractory to further GH exposure. The major impact of GH on fat and carbohydrate metabolism is, however, to antagonize the actions of insulin. the anterior pituitary is derived from a portal venous system draining the hypothalamus. Thus, the hypothalamus can modulate release of anterior pituitary hormones by secreting various factors into this portal circulation. G H release is determined by a dynamic equilibrium between the inhibitory and stimulatory hypothalamic peptides, somatostatin (SMS) and growth hormone-releasing hormone (GHRH) (Fig. 2) . The hypothalamic release of GHRH and somatostatin is, in turn, controlled through a complex network of neurotransmitters, and the hypothalamo-pituitary response may be influenced by age, sex, GH feedback, insulin, thyroid and steroid hormones, and nutritional status. The GH-IGF-1 axis, therefore, includes the hypothalamic peptides, G H and IGF-1, and a complex network of feedback between the various hormones (Fig. 2 ). We will discuss the factors involved in the neuroendocrine regulation of G H secretion in man and how the influence of nutrition may modulate this system.
SMS
REGULATION OF G H SECRETION
P H Y S I O L O G I C A L G H R E L E A S E
G H is released in a pulsatile fashion with pulses occurring every 3-4 h with the greatest release during sleep (Quabbe et al. 1966) . The amplitude and frequency of G H pulses is dependent on age, being greatest during puberty and declining with age (Finkelstein et al. 1972; Rudman et al. 1981 ; Martha et al. 1989) . Sleep, stress, exercise, and post-prandial decline in blood glucose concentration act as stimuli to G H secretion, although it is likely that most episodes of release are spontaneous (Martin, 1976) . The greatest secretion of G H occurs at night during sleep (Takahashi et al. 1968 ). Slow-wave sleep is frequently associated with G H release, but individual patterns of G H secretion during sleep show considerable heterogeneity (Adlard et al. 1987) and the time of sleep onset, rather than of slow-wave sleep, is more closely related to the nocturnal rise in G H secretion (Born et al. 1988) . Martin (1976) concluded that G H release was a sleep-related event which probably should not be considered as closely linked to, or caused by, the neural process that subserves slow-wave sleep. A more specific basis for the association between sleep mechanisms and G H release has yet to be determined.
G R O W T H H O R M O N E -R E L E A S I N G H O R M O N E
GHRH was the most recent of the hypothalamic regulatory peptides to be characterized (Guillemin et al. 1982; Rivier et al. 1982) . Its existence had been proposed much earlier (Reichlin, 1961) , but attempts to isolate it from animal hypothalami were unsuccessful because of the small quantities present and the coexistence of SMS, which interfered with the bioassays. GH-releasing factors were finally extracted from the pancreatic tumours of two patients in whom the ectopic production of GHRH had resulted in acromegaly (a condition arising from hypersecretion of GH). Three homologous peptides varying in length from thirty-seven to forty-four amino acid residues were characterized : GHRH( 1-37)NH2, GHRH( 1-40)OH, GHRH( 1-44)NH2 ( Fig. 4) .
Peptides of both forty and forty-four residues have been extracted from human hypothalamic fragments and are identical to the pancreatic peptides (Ling et al. 1984 ). There has been considerable debate as to which is the native hormone, although it is likely that both the forty-four and forty residue peptides are important (Frohman & Jansson, 1986) . GHRH immunostaining has been demonstrated in the arcuate nucleus of the hypothalamus with fibres projecting to the median eminence and ending in contact with the portal vessels (Bloch et al. 1983) . The human GHRH gene has been characterized and mapped on chromosome 20 (Mayo el al. 1985) . It has been demonstrated in vitro that GHRH stimulates not only GH secretion but also transcription of the G H gene (Barinaga el al. 1985) . Transgenic transfer of the GHRH gene in mice results in enhanced growth (Hammer et al. 1985) . Specific receptors for GHRH have been demonstrated on rat pituitary cells in culture, and the GHRH receptor activates the adenylate cyclase-cAMP system (Frohman & Jansson, 1986) . GHRH given as an intravenous bolus selectively promotes G H release in normal subjects (Gelato et al. 1983; Grossman et al. 1983 ; Rosenthal et al. 1983) , and anti-GHRH antiserum blocks pulsatile G H releasein the rat (Wehrenberg et al. 1982~) . Studies in rats given GHRH after pretreatment with anti-somatostatin antiserum suggest that there is tonic secretion of both GHRH and somatostatin into hypophyseal portal blood. Superimposed on this are three-to four-hourly pulses of GHRH release which, in association with trough levels of SMS, generate pulses of G H (Tannenbaum & Ling, 1984) . Sampling of blood from the hypophyseal portal circulation of the rat confirms that SMS is continuously secreted but reaches trough levels at the time of G H release (Plotsky & Vale, 1985) .
S O M A T O S T A T I N
SMS was discovered when a substance that inhibited G H release was unexpectedly detected in rat hypothalami during the search for a growth hormone-releasing factor (Krulich et al. 1968 ). This factor was subsequently extracted from ovine hypothalamic fragments and proved to be a tetradecapeptide which was called 'somatostatin' (Brazeau el al. 1973) (Fig. 4 ). This name is perhaps inadequate; SMS possesses many physiological and pharmacological functions beyond the regulation of G H secretion. It is widely distributed within the nervous system, gut and both endocrine and exocrine glands, and it acts as a neurotransmitter as well as an endocrine hormone; for example, SMS is synthesized in the pancreas and inhibits secretion of insulin, glucagon, and the exocrine secretions of the gut (for a full review, see Reichlin, 1983a,b) .
There is now ample evidence for a physiological role of SMS in the control of GH secretion. The administration of anti-somatostatin antiserum increases trough levels of G H and, in rats, reverses the inhibitory effect on G H release of stress and starvation (Arimura et al. 1976; Terry & Martin, 1981; Wehrenberg et al. 1982b ). The simultaneous administration of SMS with GHRH blocks the G H response to GHRH in man (Davies et al. 1985b) .
Both GHRH and SMS are found in the peripheral circulation. Some authors have suggested that these circulating plasma levels reflect hypothalamic secretion (Argente et al. 1987 ) but this seems unlikely, as circulating levels of GHRH and SMS are normal in GHdeficient children, show no relationship to G H levels, and are modulated by food intake (Sopwith er al. 1985 (Sopwith er al. , 1986 (Sopwith er al. , 1987 ; Rosskamp et al. 1 9 8 7~) . It is probable that peripheral levels of these hormones are largely derived from the gut.
I N S U L I N -L I K E G R O W T H F A C T O R S ( I G F / S O M A T O M E D I N S )
The 'somatomedin hypothesis' arose from the observation that cartilage from hypophysectomized rats was unresponsive to G H added in vitro, but incorporated sulphate in response to normal rat serum and serum from GH-treated hypophysectomized rats (Salmon & Daughaday, 1957) . It was suggested that there was a 'sulphation factor' or 'somatomedin' which mediated the effects of GH. The GH-dependency of this factor was confirmed by subsequent studies showing low levels of sulphation factor activity in hypopituitary patients, high levels in acromegalic patients, and raised levels in hypopituitary patients given human-GH (Hall, 1971) .
The somatomedin peptides were first purified from human plasma and have a molecular weight of approximately 7500000 and show marked structural homology with pro-insulin (Rinderknecht & Humbel, 1978a, b) . They possess a number of insulin-like properties, notably a potent hypoglycaemic effect, and, therefore, have been named 'insulin-like growth factors (IGF)'. In man, there are two distinct somatomedins ; somatomedin-C or (IGF-1) and IGF-2. A recent consensus has suggested that the term 'somatomedin' should be used as a generic designation with the specific growth factors referred to as IGF-1 and IGF-2 (Daughaday et af. 1987). IGF-I is highly GH-dependent, has potent mitogenic activity in vitro, and its serum levels generally reflect G H activity, being high in acromegaly and low in G H deficiency (Hall & Sara, 1984) .
The IGF, unlike most other peptide hormones, are associated in serum with specific binding proteins. The two major species of binding protein are the predominant GHdependent protein (IGFBP-3) of approximately 150000 molecular weight, and a GHindependent protein of approximately 30000 (IGFBP-1) (Letter, 1990) . Whereas levels of IGFBP-3 show little, if any, diurnal variation, IGFBP-1 appears to be metabolically regulated. Serum levels of IGFBP-I show a diurnal rhythm with an inverse relationship to insulin and may have a critical role in maintaining glucose homeostasis (Baxter & Cowell, 1987; Yeoh & Baxter, 1988) . A rise in IGFBP-1, through increasing the bound fraction of IGF, could be protective against the hypoglycaemic, insulin-like effects of IGF-I, and inhibit the growth-promoting effects, when insulin levels and fuel substrate are low (Taylor et al. 1990) .
There is considerable debate as to whether the somatomedins act in an endocrine, paracrine or autocrine fashion. The role of circulating IGF-1, which derives mainly from the liver, remains unclear, but as discussed below it may be important in G H feedback. Studies in which GH and IGF-I have been infused into the hindlimb of rats have demonstrated a local growth-promoting effect which is abolished by antiserum to IGF-1 (Schlechter et af. 1986; Isaksson et al. 1987) . These results are generally consistent with the ' somatomedin hypothesis' that the growth-promoting action of G H is mediated through IGF-I, but shift the emphasis away from circulating IGF-1 produced in the liver and towards locally generated IGF-1.
G H F E E D B A C K
There is good evidence that G H modulates its own secretion, but whether by a direct or indirect effect remains unclear. The G H response to pharmacological stimuli such as insulin-induced hypoglycaemia and arginine, and to physiological stimuli such as sleep and exercise is attenuated by pretreatment with human G H (Abrams et af. 1971 ; Hagen et al. 1972; Mendelson er al. 1983 ). This inhibition of response to both pharmacological and physiological stimuli could be a direct action of GH, or be mediated indirectly by GHinduced IGF-I production or by other metabolic factors under the influence of GH, such as a rise in free fatty acid (FFA) levels. Both G H and IGF-I may exert feedback at either the hypothalamic or pituitary level; at the hypothalamus, control of G H release could, in turn, be mediated either through altered GHRH or SMS secretion. G H pretreatment blocks the response to GHRH, both when given acutely before a rise in serum IGF-I can be generated (Ross et al. 1987a ) and after prolonged treatment associated with a rise in IGF-I levels (Nakamoto et al. 1986; Rosenthal et al. 1986 ). G H can therefore regulate its own secretion independently of circulating IGF-I , although the mechanism for this may require local generation of IGF-I in the hypothalamus or pituitary. Circulating IGF-I may offer a further regulatory influence on GH secretion. There is evidence in man to suggest that G H feedback occurs under hypothalamic control, through SMS, since pyridostigmine, an acetylcholinesterase inhibitor that reduces SMS release, blocks G H feedback (Ross et al. 1987~ ). In addition, there is good evidence from both in vivo and in vitro studies in the rat that G H and IGF-I induce release of hypothalamic SMS (Sheppard et al. 1978; Tannenbaum, 1980; Tannenbaum et al. 1983; Berelowitz et al. 1981 ) and that IGF-I but not SMS will suppress pituitary GH mRNA (Namba et al. 1989) . Receptors for IGF-I and IGF-2 are widely distributed within the central nervous system of rats, particularly in the pituitary gland and the median eminence of the hypothalamus (Lesniak et al. 1988; Ocrant et al. 1989) . Notably, reduced energy intake sufficient to lower plasma IGF-I levels is associated with an increase in IGF-I receptors in the median eminence (Bohannon et al. 1988 ).
In man, repetitive administration of GHRH at two-hourly intervals is accompanied by attenuation of the G H response, but with a continuous infusion of GHRH there is augmentation of the amplitude of endogenous G H secretory pulses (Shibasaki et al. 1985; Vance et al. 1985) . The likely explanation for these findings is that thefrequency of GH pulses is determined by variations in background SMS activity and the amplitude by a pulse of GHRH coincident with trough levels of SMS. The pulse of G H contributes in turn to inhibition of further G H release through the feedback loop, provoking an increase in SMS release. A further level of control is suggested by the observation that GHRH may itself exert feedback stimulation of SMS release (Lumpkin et al. 1985) .
T H Y R O I D A N D S T E R O I D H O R M O N E S
Thyroid hormones, glucocorticoids and sex steroids all influence G H secretion. Hypothyroidism in man is associated with decreased G H release on provocative testing and spontaneous nocturnal G H secretion shows a reduction of G H pulse amplitude in children with severe hypothyroidism, with recovery over 3-6 months after thyroxine replacement (Iwatsubo et al. 1967; Buchanan et al. 1988 ). Regulation of G H secretion has been more clearly defined in animal models or in vitro systems. The rat G H gene contains thyroid-and glucocorticoid hormone-responsive elements and these may independently promote increased G H synthesis (Gick & Bancroft, 1987; Wight et al. 1987) . Glucocorticoids may have net positive or negative influences on GH secretion according to whether the predominant effect is on hypothalamic SMS and GHRH release, or directly on the pituitary somatotroph (Nakagawa et al. 1987) . Dexamethasone (a potent glucocorticoid) will ablate the inhibitory effect of IGF-I on G H release by rat pituitary cells in vitro (Lamberts er al. 1989) . In man, short-term steroid treatment augments G H release but long-term treatment suppresses G H release (Burguera et al. 1990) .
Oestrogens are probably responsible for the differences in G H release between men and women, in particular with regard to the rise in G H secretion seen during puberty, and may account for the sexual dimorphism of G H secretion in other species (Conway et al. 1989 ).
It is not clear whether the effects of androgens are mediated through oestrogens or act independently. Oestrogens, both endogenous and administered, are known to enhance basal and stimulated G H release. Women have higher basal levels of G H than men (Unger et al. 1965) , especially during the high oestrogenic phase of the menstrual cycle (Frantz & Rabkin, 1965) , and oestrogen pretreatment of normal men increases both basal and stimulated GH secretion (Frantz & Rabkin, 1965; Merimee et al. 1966) . Androgens increase the GH response to provocative stimuli in prepubertal children (Laron et al. 1972) , but have no effect on either the basal or stimulated G H secretion of adult women (Merimee et al. 1969 , Merimee & Fineberg, 1971 ). Ho et al. (1987) have demonstrated a close correlation between oestradiol levels and G H pulse amplitude. Oestradiol appeared to increase G H pulse amplitude and duration rather than frequency. Oestrogen pretreatment does not alter the G H response to exogenous GHRH, suggesting that its effects are to augment endogenous GHRH release (Ross et al. 19876 ).
R. J. M. ROSS A N D c . R. B U C H A N A N
N E U R O T R A N S M I T T E R S A N D G H R E L E A S E
Neurons containing catecholamines, acetylcholine, the amino-acid neurotransmitter yaminobutyric acid (GABA), and the opioid peptides are found in the hypothalamus. There is a complex interaction between the various neurotransmitters and both SMS and GHRH, but as yet, which neurotransmitters have the most important role in physiological G H secretion remains unclear.
Studies with a-adrenergic agonists and antagonists suggest that a-2 adrenergic receptor stimulation is important in G H release stimulated by hypoglycaemia (Tatar & VigaS, 1984) . The a-2 agonist, clonidine, stimulates GH release in man and is used as a test of G H secretion (Lanes & Hurtado, 1982) . a-2 adrenergic stimulation may cause G H release through increased GHRH secretion, as rats depleted in GHRH fail to respond to clonidine (Katakami et (Locatelli et al. 1986 ). Thus, findings in animals suggest that the effect of cholinergic manipulation on G H secretion is mediated through hypothalamic SMS secretion. However, in man the mechanism of action is less clear (Freeman et al. 1990 ).
Basal GH secretion is stimulated by GABA and by a number of GABA-ergic drugs such as muscimol, baclofen, and diazepam. In contrast, GABA is able to reduce the GH response to insulin-induced hypoglycaemia. A dualistic role of GABA on dopamine secretion and G H release has been suggested (Bercu & Diamond, 1986) . The opioid peptides also stimulate G H release, an effect blocked by low doses of naloxone (Stubbs et al. 1978 ; Grossman, 1983) . The G H response to maximal doses of GHRH is augmented by the opioids, suggesting that they act independently of GHRH (Delitala et al. 1987) .
The contribution of serotonin remains controversial as both stimulatory and inhibitory influences have been reported in man. The role of histamine is also difficult to establish because of the poor neuropharmacological specificity of its antagonists, which frequently also possess anti-cholinergic and anti-dopaminergic properties. Most evidence favours an inhibitory role for histamine on both basal and stimulated G H release (Netti et al. 1981) . 
THE I N F L U E N C E OF N U T R I T I O N O N G H SECRETION
The nutritional state of subjects and patients has a profound effect on G H secretion and IGF-1 levels. As discussed below, metabolic factors, obesity, fasting, anorexia, diabetes mellitus, malnutrition and catabolic states interact with the GH-IGF axis, resulting in differing profiles of G H and I G F secretion (Fig. 5) . Serum IGF-I shows a close correlation with nitrogen balance in sick or malnourished patients and is a sensitive indicator of nutritional status (Clemmons et al. 1985; Minuto et al. 1989) .
M E T A B O L I C F A C T O R S
Several metabolic factors influence GH secretion, in particular glucose, insulin, FFA and amino acids. Acute hypoglycaemia is a potent stimulus to G H secretion, and it is likely that GH normally functions as a counter-regulator of glucose levels through effects on glucose production, glucose utilization and lipolysis, although this role is not entirely clear (Davidson, 1987; De Feo et al. 1989) . Insulin-induced hypoglycaemia is well established as a clinical test for evaluating the integrity of the hypothalamo-pituitary axis through provocation of GH release (Frasier, 1974) .
In contrast, an acute rise in glucose after oral or intravenous administration to normal individuals will inhibit GH release and the G H response to GHRH (Davies et al. 1984; Sharp et al. 1984; Garrel et al. 1989) . Enhanced cholinergic tone, using pyridostigmine, will counteract this suppressive effect of glucose on GH release probably through effects on SMS secretion (Balzano et al. 1989 ). However, neither acute nor sustained hyperglycaemia has a consistent suppressive effect on G H secretion in the rat (Imaki et al. 1986; King et al. 1986 ).
In addition to the indirect stimulatory effect of insulin through hypoglycaemia on GH release, it has a direct suppressive effect on G H synthesis by pituitary cells in vitro through inhibition of G H gene transcription (Yamashita & Melmed, 1986 ), suggesting a mechanism for increased G H production during periods of reduced nutrition and the reverse with hyperinsulinaemia and obesity (Ahmad et al. 1989 positive and negative effects on G H gene expression according to the presence of other regulatory factors (e.g. dexamethasone and triiodothyronine) (Isaacs et 01. 1987) .
The fatty acids will, like glucose, inhibit GH release and the GH response to GHRH (Imaki et (11. 1985 (Imaki et (11. , 1986 Sartin et al. 1988) , and there is evidence in vitro that the effect of FFA is exerted at the pituitary level (Casanueva et al. 1987) . It has been suggested that G H feedback is in part mediated by FFA (Rosenbaum et al. 1989) , but this seems unlikely as FFA levels rise during a prolonged fast in association with augmented GH release (Ho el nl. 1988) .
Intravenous infusion of essential amino acids, the fundamental requirements for protein metabolism, will stimulate GH release in humans and non-primate species (Knopf et al. 1965 ; Davis, 1972) . Arginine, histidine and lysine are particularly potent. This may explain the post-prandial rise in plasma G H after a protein meal (Sukkar et al. 1967 ) and has formed the basis of a standard provocation test for GH secretion (Merimee et al. 1965,  1969) . The mechanism whereby GH release is stimulated has not been studied for many amino acids, but arginine appears to act via the hypothalamus ; sex-steroid status will influence the response to arginine (Merimee et ul. 1966) , arginine pretreatment will enhance GHRH-stimulated GH release, probably by suppression of endogenous SMS (Alba-Roth et ul. 1988), and antimuscarinic agents such as atropine suppress arginine-induced G H secretion (Casanueva et (11. 1984) . Obesity and high plasma levels of phenylalanine in children with phenylketonuria have been reported to impair the G H response to arginine infusion (El-Khodary et ul. 1971 ; Rosskamp et al. 1987~) .
R. J. M. R O S S A N D c . R. R U C H A N A N
O B E S I T Y
Obese subjects show attenuated G H responses to most stimuli including insulin-induced hypoglycaemia and GHRH (Williams et al. 1984; Kopelman et ul. 1985) . Despite this, obese children tend to grow at an above-average rate. Circulating IGF-1 levels are higher in obese patients and have been reported to show a negative correlation with the GH response to GHRH (Loche et al. 1987) , although not all groups have found this relationship (Davies et ul. 1 9 8 5~; Rosskamp et al. 19876) . The reduced response to GHRH returns to normal after weight loss and it is likely that it is a consequence rather than a cause of obesity (Williams et al. 1984; Csizmadi et al. 1989 ). The obese rat, which is hyperinsulinaemic, shows low pituitary GH mRNA levels (Ahmad et al. 1989) . The suppressed GH secretion in obesity may, therefore, be a consequence of the hyperinsulinaemia or increased IGF-I levels sometimes seen in this state.
Since GH has nitrogen-preserving and lipolytic actions (Davidson, 1987) , it may be of benefit in obese patients attempting to lose weight (Thorner & Vance, 1988) . Short-term GH administration was effective in decreasing the loss of lean body mass in individuals on restricted dietary intake, but fat loss was not accelerated (Clemmons et al. 1987) . The same group have also demonstrated that the dietary carbohydrate content determines responsiveness to GH in obese patients on an energy-restricted diet (Snyder et al. 1989) . The higher the carbohydrate content of the restricted diet the lower the N excretion of the patients. Interestingly in this second study patients showed increased body fat loss on G H treatment . IGF-I levels declined gradually over the 5 d. The GH response to GHRH was the same at the end of the fast as the beginning, suggesting that the changes in G H secretion were not due to changes in the pituitary sensitivity to GHRH. Similar elevation of G H secretion on food restriction has been observed in most species studied (Atinmo et al. 1978; Driver & Forbes, 1981 ; Scanes e f Breier e f al. 1988; Cella et al. 1989; Foster et al. 1989) . A notable exception is the rat, in which G H levels fell on fasting, in response to increased SMS release, and catch-up growth on refeeding was associated with enhanced GH secretion through increased GH pulse amplitude (Tannenbaum et al. 1979; Mosier et al. 1985) .
It is well recognized that fasting and malnutrition are associated with low IGF-I levels. From refeeding studies in both man and the rat it appears that both energy and protein are required for the normal production of IGF-I (Phillips & Unterman, 1984) . Anorexia nervosa is associated with elevated basal G H levels similar to that seen in fasted subjects, and again the G H response to GHRH is the same as control subjects (Casanueva et al. 1987; De Marinis et al. 1988) . The findings in fasting and anorexia are the converse of obesity; greater GH secretion and low IGF-I levels. Possibly the lack of IGF-I feedback results in greater G H release.
D I A B E T E S
In contrast to normal subjects, the hyperglycaemia of diabetes rnellitus and sick patients with insulin resistance is associated with augmented rather than depressed G H secretion (Asplin ef al. 1989 ; Ross e f al. 1990 ). Patients with insulin-dependent diabetes have greater amplitude and frequency of G H pulses and higher interpulse G H levels compared with controls (Asplin et al. 1989 ), yet they have lower IGF-I levels than controls. The GH response to GHRH in diabetes has been reported to be greater than, or similar to, that of controls (Press et al. 1984) . A 'normal' response to GHRH, however, would be inappropriate in the presence of hyperglycaemia. The abnormality of G H secretion seen in diabetics appears to correlate inversely with their diabetic control. In diabetics and children with kwashiorkor, oral glucose does not provoke the usual suppression of G H secretion (Press ef al. 1984; Pimstone et al. 1967) . Thus, the pattern of G H secretion seen in diabetics is similar to that seen in fasted subjects and may well reflect the consequences of intracellular starvation under conditions of insulin deficiency.
M A L N U T R I T I O N A N D C A T A B O L I C S T A T E S
Early observations on G H secretion in malnourished states were mainly in children with protein and/or energy deficiency of kwashiorkor and marasmus (Becker, 1983) . Plasma GH levels were high in the presence of low insulin, albumin and amino acid levels and returned to normal within days of refeeding with protein (Pimstone et al. 1966 (Pimstone et al. , 1968 . Oral feeding of such children with essential amino acids, but not an intravenous glucose load, provoked a fall in GH within just 30 min (Milner, 1971 a, b) , and the acute rise in GH after arginine infusion was obtunded (Graham et al. 1969; Soliman et al. 1986 ). This reversal of the normal pattern of G H response to metabolic cues was clearly an adaptive phenomenon in nutritional deprivation, although the mechanism and purpose were unclear.
A paradox existed, as depressed amino acid levels were associated with high GH levels when the supply of substrate for growth was deficient. Infusions of amino acids singly or in combination failed to identify an individual amino acid capable of reversing these changes in G H secretion and a similar pattern of G H release could not be reproduced by manipulation of, in particular, the branched-chain amino acids released during starvation and gluconeogenesis. Realization that sulphation (somatomedin, IGF) activity was reduced in protein malnutrition helped focus attention on how G H might be diverted from its growthpromoting effects to acquire a more important role in the regulation of available metabolic fuels (Grant et al. 1973; Shapiro et af. 1978; Phillips, 1986 ). This response is not restricted to the malnourished child, but occurs similarly in fasted healthy or obese adults (see p. lo), and particularly in undernourished critically ill patients (Phillips & Unterman, 1984; Freeman et al. 1989 ; R. J. M. Ross, unpublished results).
Critically ill, septic patients show an increase in interpulse G H levels compared with fasted controls, yet have similar G H pulse frequency and mean G H levels throughout 24 h (Freeman el al. 1989) (Fig. 6 ). There has been no detailed analysis of the pattern of G H secretion in protein-nergy malnourished children, with single basal G H levels having formed the basis of most published studies. The elevated circulating levels of G H in protein-energy malnutrition have, however, been shown to result from enhanced secretion, rather than impaired clearance, by demonstration of a normal GH disappearance time during SMS infusion (Pimstone et al. 1975) .
Overall, the findings suggest that catabolic states and malnutrition are associated with low serum IGF-! levels and enhancement of G H secretion. This occurs through an increase in interpulse GH levels and possibly in GH pulse amplitude rather than increased pulse frequency. An explanation may be that circulating or centrally generated IGF-1 is important in GH feedback and that low levels of IGF-1 lead to decreased hypothalamic SMS release and thus an increase in basal GH release. The low IGF-1 levels suggest these patients have a 'GH-resistant' state.
In normal or diabetic rats, this effect of protein restriction appears to be achieved through a post-receptor defect in the GH-tissue axis since GH binding to liver is normal but IGF-1 production reduced (Maes et al. 1986; Maiter et al. 1989) . Insulin deficiency, however, may additionally result in reduced G H binding to its liver receptors (Maiter et af. 1989) .
With increased understanding of the pathophysiology of malnutrition and catabolic states, it is hoped that advances may be achieved in the clinical management of such disorders through manipulation of one or more components of the GH-IGF axis. It remains to be seen whether G H or IGF-1 has a therapeutic role to improve the nutritional state of sick patients. There is already good evidence that treatment with G H can improve N balance in fasted normal subjects and patients following gastrointestinal surgery and thus potentially accelerate recovery (Manson & Wilmore, 1986; Ward et al. 1987; Ziegler er al. 1988) . In these patients metabolic regulatory mechanisms are so adapted that the G H levels necessary for such effects are only obtained with relatively 'high' doses of exogenous GH. A recent exciting observation is that fasted mice treated with IGF-1 showed less weight loss than untreated mice (O'Sullivan et al. 1989 ).
In the malnourished patient the altered relationship between GH and IGF-1 may represent a protective response. In the fasted state, hypoglycaemia is a persistent danger and appropriate substrates are required for the liver to synthesize essential proteins. The fall in IGF-I may be an essential permissive event to allow muscle catabolism to yield metabolic fuels and avoid the hazards of hypoglycaemia. Similarly, the accompanying rise in G H levels promotes insulin resistance and lipolysis, both protective metabolic changes during acute and prolonged dietary restriction.
Considerable advances have been made in recent years in our understanding of the factors regulating G H secretion, and its effects on growth and intermediary metabolism. The recent availability of recombinant G H and IGF, characterization of the GH receptor (Waters et al. 1990 ) and the GH-and IGF-binding proteins will greatly enhance our knowledge of this field and may provide new therapies for some nutritional disorders.
